NASDAQ:HGSI - Human Genome Sciences Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Human Genome Sciences, Inc. (HGS) is a biopharmaceutical company. The Company's products include BENLYSTA (belimumab) for systemic lupus erythematosus (SLE) and raxibacumab for inhalation anthrax. HGS continues to deliver raxibacumab to the United States Strategic National Stockpile (SNS) for emergency use in treating inhalation anthrax. In addition to the Company's internal pipeline, it has financial rights to two drugs that GlaxoSmithKline (GSK) has advanced to late-stage development. These include darapladib and albiglutide. A randomized Phase 2 trial is evaluating mapatumumab in combination with Nexavar (sorafenib) for the treatment of advanced hepatocellular cancer. The Company manufactures multiple protein and antibody drugs for use in research, clinical and commercial activities. It produces and purifies these protein and antibody drugs in three process development and manufacturing facilities. In August 2012, GlaxoSmithKline plc acquired HGS.

Receive HGSI News and Ratings via Email

Sign-up to receive the latest news and ratings for HGSI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:HGSI
Previous Symbol
CUSIPN/A
Phone+1-301-3098504

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A
Market Cap$0.00
OptionableNot Optionable

Human Genome Sciences (NASDAQ:HGSI) Frequently Asked Questions

What is Human Genome Sciences' stock symbol?

Human Genome Sciences trades on the NASDAQ under the ticker symbol "HGSI."

Has Human Genome Sciences been receiving favorable news coverage?

Media coverage about HGSI stock has trended somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Human Genome Sciences earned a coverage optimism score of 2.0 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next several days.

How do I buy shares of Human Genome Sciences?

Shares of HGSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Human Genome Sciences' official website?

The official website for Human Genome Sciences is http://www.hgsi.com.

How can I contact Human Genome Sciences?

Human Genome Sciences' mailing address is 14200 Shady Grove Rd, ROCKVILLE, MD 20850-7464, United States. The biopharmaceutical company can be reached via phone at +1-301-3098504.


MarketBeat Community Rating for Human Genome Sciences (NASDAQ HGSI)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  113 (Vote Outperform)
Underperform Votes:  122 (Vote Underperform)
Total Votes:  235
MarketBeat's community ratings are surveys of what our community members think about Human Genome Sciences and other stocks. Vote "Outperform" if you believe HGSI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HGSI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/13/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel